COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Atopix Therapeutics is a clinical-stage Oxford biotech developing oral CRTH2 antagonist small molecules and topical candidates for Th2-mediated diseases, with lead OC459 in Phase 2 and ATX2417 Phase‑1‑ready.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors